Fig. 2

Characterization of the expanded HSCs CD34+ progenitor. A and B, the comparison of CFU assay results between the two groups treated with SFT (SCF, Flt3-L and TPO) and SFTG36 (SCF, Flt3-L, TPO, GM-CSF, IL-3 and IL-6) cocktail cytokines and morphological analysis by Wright-Giemsa staining. C–E, both expanded cell populations were analyzed using flowcytometry and cell counting on the day 7. C, Analyses of fold expansion and D, cell viability of both groups. E, the phenotypic analysis of the expanded cells for CD45, CD34 and CD45/CD34 markers are shown as flowcytometry zebra plots. The comparison of markers expressions ****P < 0.0001, indicating a statistically significant increase in the expanded SFTG36 cell population compared to SFT cell population. p<0.01 was considered significant (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001). Data are demonstrated as mean ± SD, n =4.